In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

CAR T-cell therapy is being adapted for clear cell renal cell carcinoma, targeting CAIX and CD70 to improve efficacy and safety. Early trials like COBALT-RCC and TRAVERSE show promising disease ...

In the rapidly moving field, questions remain regarding long-term safety, durability of remission, and the FDA’s approach to ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

While rare, secondary cancers after CAR T-cell therapy have been reported, leading the FDA to mandate boxed warnings on all approved therapies. In a first, targeted therapy was used to treat a T-cell ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

Translating academic practices into a community oncology setting requires meaningful adaptations to successfully integrate practices like adoptive cell therapy, CAR-T therapies, or TCR-T therapies, ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...